Search

Displaying results 4101 - 4110 of 8520 in total
  1. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharma...

  2. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

  3. Drug

    Tiotropium

    go.drugbank.com/drugs/DB01409
    ApprovedInvestigational

    [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]

  4. Drug

    Cobalt

    go.drugbank.com/drugs/DB14574
    ApprovedWithdrawn

    It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments.

  5. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    [L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized

  6. Drug

    Hydronidone

    go.drugbank.com/drugs/DB06299
    Investigational

    Hydronidone has antifibrotic activity.

  7. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra P...

  8. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  9. Drug

    Filanesib

    go.drugbank.com/drugs/DB06040
    Investigational

    Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.

  10. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.